Bioasis Technologies (Bioasis Technologies) Asset Impairment Charge : $0.00 Mil (TTM As of Nov. 2022)

View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Asset Impairment Charge?

Bioasis Technologies's Asset Impairment Charge for the three months ended in Nov. 2022 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Nov. 2022 was $0.00 Mil.

Bioasis Technologies Asset Impairment Charge Historical Data

The historical data trend for Bioasis Technologies's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Asset Impairment Charge Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Asset Impairment Charge

Get a 7-Day Free Trial

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Bioasis Technologies Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Bioasis Technologies Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (Bioasis Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.